gastrointestinal stromal tumour
Oncology · 2007–2021
4decisions
3medicines
1carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ripretinib Advanced gastrointestinal stromal tumour (GIST) after failure of or intolerance to imatinib and sunitinib. | Jul 2021 | Recommended with restriction | 3 individuals |
| imatinib Adjuvant treatment for 12 months of patients at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST). | Nov 2009 | Not recommended | no section in document |
| sunitinib malate Gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance. | Mar 2008 | Not recommended | no section in document |
| sunitinib malate treatment of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour (GIST) after failure of PBS-subsidised imatinib… | Mar 2007 | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.